GSK has entered into an exclusive licensing agreement with Chinese biotech Suzhou Siran Biotechnology (SiranBio), securing global rights to the company’s early-stage small interfering RNA (siRNA) therapy, SA030, in a deal worth up to $1.005 billion in potential milestone payments. The agreement, which covers all markets outside mainland China, Hong Kong, Macau, and Taiwan, adds a novel cardiometabolic asset to the UK pharmaceutical giant’s growing oligonucleotide pipeline.
Under the terms of the arrangement, GSK has paid an upfront sum that has not been formally confirmed, though some outlets have reported the figure as $55 million. Potential milestone payments could bring the total value of the deal to up to $1.005 billion. Should SA030 reach the market, SiranBio will also be entitled to tiered royalties on net sales across licensed territories.
A Novel Mechanism Targeting Visceral Fat
SA030 is a long-acting siRNA candidate designed to silence activin receptor-like kinase 7 (ALK7), a protein increasingly recognised for its role in regulating abdominal fat accumulation. Unlike the majority of RNA therapeutics, which are directed at the liver, SA030 employs an adipocyte-directed delivery technology engineered to home in on visceral adipose tissue (VAT) — the metabolically active abdominal fat depot associated with insulin resistance, cardiovascular complications, and systemic inflammation.
SiranBio notes that preclinical studies have demonstrated a differentiated, long-acting profile for SA030, with evidence of reduced VAT while preserving lean muscle mass. The company states that lowering VAT in patients with chronic inflammatory conditions affecting the liver, lung, and kidney could have a greater impact on survival than managing the underlying disease alone. The candidate recently entered Phase I clinical trials (NCT07479862), evaluating its tolerability and pharmacokinetics in individuals with overweight or obesity. SiranBio will retain responsibility for the Phase I programme before handing over development to GSK upon its completion.
Kaivan Khavandi, Senior Vice President and R&D Head of Respiratory, Immunology and Inflammation at GSK, underscored the unmet need driving the deal:
“Cardiometabolic disease is the leading cause of death in most patients with chronic inflammatory conditions affecting the liver, lung and kidney. This risk is driven by multiple factors, so novel complementary approaches are urgently needed.”
“SA030 builds on our emerging pipeline targeting inflammation, fibrosis, and vascular drivers of disease, and may help improve outcomes for patients,” Khavandi added.
Complementary to GLP-1 Agonists and SGLT2 Inhibitors
SA030’s mechanism sets it apart from the current crop of weight-loss therapies dominating the market. Rather than engaging the glucagon-like peptide 1 receptor agonist (GLP-1RA) pathway, the asset directly targets the biological processes underpinning cardiometabolic risk. SiranBio positions SA030 as complementary to both GLP-1 agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors, raising the prospect of future combination treatment strategies designed to address residual cardiometabolic risk from multiple therapeutic angles.
One significant point of differentiation is SA030’s potential to preserve lean muscle mass — a concern that has attracted scrutiny in relation to blockbuster GLP-1RA therapies, where muscle loss alongside fat reduction has emerged as a clinical consideration. By addressing VAT reduction through a distinct mechanism, SA030 may offer an approach that circumvents this issue entirely.
Zhiwei Yang, PhD, Founder and CEO of SiranBio, commented on the rationale for the partnership:
“GSK’s resources and clinical development capabilities have the potential to accelerate the transformation of our pipeline into therapeutics, benefitting more people in the reduction of fat and related chronic diseases.”
Expanding GSK’s Oligonucleotide Pipeline
GSK has described the SiranBio agreement as consistent with its broader strategy to expand its oligonucleotide therapeutics pipeline, which spans both siRNA and antisense oligonucleotide (ASO) modalities. The company views these technologies as capable of addressing disease pathways not readily accessible through conventional small molecule or biologic therapies.
GSK’s existing oligonucleotide portfolio is already substantial. The company’s lead programme, bepirovirsen, is a collaboration with Ionis Pharmaceuticals currently in two Phase III trials as a potential functional cure for hepatitis B virus infection. The broader portfolio also includes a collaboration with Arrowhead Pharmaceuticals for fatty liver disease, multiple assets acquired from Wave Life Sciences, and a nonexclusive licence to Elsie Biotechnologies’ platform.
The SiranBio deal is the second siRNA licensing agreement GSK has struck with a Chinese biotech in rapid succession. Earlier this year, the company paid $40 million upfront for two early-stage siRNA candidates from Frontier Biotechnologies, in a deal also valued at approximately $1 billion, targeting kidney diseases driven by inflammation. Over the past two years, GSK has signed agreements with Hengrui, Hansoh, Chimagen, and Frontier Biotech, reflecting a sustained strategic focus on Chinese biotech partnerships in the RNA therapeutics space.
Cardiometabolic Ambitions Beyond the GLP-1 Race
The SiranBio agreement forms part of a broader push by GSK to establish a foothold in cardiometabolic disease without directly entering the increasingly competitive GLP-1RA arena. While rivals such as Eli Lilly and Novo Nordisk have staked out dominant positions in the weight-loss market, GSK is pursuing alternative mechanisms aimed at addressing the downstream health consequences of obesity, including liver and kidney dysfunction.
In the metabolic dysfunction-associated steatohepatitis (MASH) space, GSK is running the Phase III ZENITH programme investigating efimosfermin alfa, an FGF21 analogue. Its pipeline in this area also includes gatuzosiran (GSK532990), an HSD17B13-directed siRNA candidate. In February 2026, the company also acquired 35Pharma for $950 million, bringing in the pulmonary hypertension asset HS235, which GSK’s Chief Scientific Officer Tony Wood has noted for its potential metabolic health benefits, describing its mechanism as enabling “fat-driven weight loss”.
With SA030 now in its portfolio, GSK has secured a potentially first-in-disease asset that targets the same downstream metabolic consequences of obesity that many existing therapies fail to fully resolve. Whether that early promise translates into clinical benefit will depend on the data generated across both Phase I and subsequent trials, but the deal reflects a clear thesis: that managing cardiometabolic risk will require more than one therapeutic mechanism, and that RNA-based approaches may play a central role in addressing what remains a substantial unmet need.
